Nykode Therapeutics ASA — AGM Information 2021

Nov 23, 2021

Company Announcement

Vaccibody AS – Notice of Extraordinary General Meeting

Oslo, Norway, November 23, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, hereby calls for an Extraordinary General Meeting (EGM) to be held at meeting room Toppsenteret - FAROS –- Building H – Floor 5 in Gaustadalléen 21, Oslo, Norway at 10:00 CET on November 30, 2021.

The notice of the EGM is attached. All documents regarding the EGM are also available at the Company's website: www.nykode.com/media/news-and-announcements.

The following items are on the agenda: (i) Change of the company's name to Nykode Therapeutics AS, (ii) Extension of expiry date for warrants and (iii) Election of members to the Nomination Committee.

Shareholders representing 44.40 % of the outstanding shares have already undertaken to vote in favor of the items on the agenda.

Due to the ongoing corona virus pandemic, the Board encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to vote by proxy. The proxy form will be found at the above weblink.

For further information, please see the Company's website or contact CFO Harald Gurvin. Please see below for contact details.

About Nykode Therapeutics*)

Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.

The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com

Contact for Vaccibody:

CFO Harald Gurvin Vaccibody AS Cell: +47 975 20 363 hgurvin@vaccibody.com

Vaccibody AS

Oslo Science Park Gaustadalléen 21 N-0349 Oslo, Norway

*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.

Forward-looking statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forwardlooking statements.